OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The platform is being introduced to expand access to treatments for people living with chronic conditions
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Subscribe To Our Newsletter & Stay Updated
